D. E. SHAW & CO, L.P. — Form SCHEDULE 13D/A
Filed July 1, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 28/100
What the filing says
D.E. Shaw & Co, L.P. and affiliated entities (Valence Portfolios and Cogence) sold approximately 5,878,258 common shares of Gossamer Bio, Inc. (GOSS) between June 12–July 1, 2026 at prices ranging from $0.15–$0.18 per share, reducing combined beneficial ownership from initial position to 40,630,726 shares (8.3% of 488.8M outstanding). Counterparties were Valence (7.8%, sold ~4.2M shares) and Cogence (0.4%, sold ~285K shares); David E. Shaw retains indirect control via management entities but disclaims direct ownership.
Why this rating
Large seller liquidation at depressed price ($0.16–$0.18) signals weak confidence; material share count (~1.2% of float) but immaterial to D.E. Shaw's AUM. For Gossamer Bio (micro-cap biotech), loss of sophisticated backer is reputationally negative but not existential given minimal remaining Shaw stake.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.